286 related articles for article (PubMed ID: 20350666)
1. Rituximab-associated infections.
Gea-Banacloche JC
Semin Hematol; 2010 Apr; 47(2):187-98. PubMed ID: 20350666
[TBL] [Abstract][Full Text] [Related]
2. Reactivation of hepatitis B virus with rituximab.
Tsutsumi Y; Kanamori H; Mori A; Tanaka J; Asaka M; Imamura M; Masauzi N
Expert Opin Drug Saf; 2005 May; 4(3):599-608. PubMed ID: 15934864
[TBL] [Abstract][Full Text] [Related]
3. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.
Tsutsumi Y; Tanaka J; Kawamura T; Miura T; Kanamori H; Obara S; Asaka M; Imamura M; Masauzi N
Ann Hematol; 2004 Jan; 83(1):58-60. PubMed ID: 14513286
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in chronic lymphocytic leukemia.
Jaglowski SM; Byrd JC
Semin Hematol; 2010 Apr; 47(2):156-69. PubMed ID: 20350663
[TBL] [Abstract][Full Text] [Related]
5. Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections.
Vassilopoulos D; Calabrese LH
Curr Opin Rheumatol; 2007 Nov; 19(6):619-25. PubMed ID: 17917544
[TBL] [Abstract][Full Text] [Related]
6. Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature.
Pelosini M; Focosi D; Rita F; Galimberti S; Caracciolo F; Benedetti E; Papineschi F; Petrini M
Ann Hematol; 2008 May; 87(5):405-12. PubMed ID: 18064459
[TBL] [Abstract][Full Text] [Related]
7. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases.
Cooper N; Arnold DM
Br J Haematol; 2010 Apr; 149(1):3-13. PubMed ID: 20151975
[TBL] [Abstract][Full Text] [Related]
8. Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease.
Vidarsson B; Mosher DF; Salamat MS; Isaksson HJ; Onundarson PT
Am J Hematol; 2002 May; 70(1):51-4. PubMed ID: 11994982
[TBL] [Abstract][Full Text] [Related]
9. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma.
Perceau G; Diris N; Estines O; Derancourt C; Lévy S; Bernard P
Br J Dermatol; 2006 Nov; 155(5):1053-6. PubMed ID: 17034541
[TBL] [Abstract][Full Text] [Related]
10. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis.
Esteve M; Saro C; González-Huix F; Suarez F; Forné M; Viver JM
Gut; 2004 Sep; 53(9):1363-5. PubMed ID: 15306601
[TBL] [Abstract][Full Text] [Related]
11. Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.
Tam C; Seymour JF; Brown M; Campbell P; Scarlett J; Underhill C; Ritchie D; Bond R; Grigg AP
Haematologica; 2005 May; 90(5):700-2. PubMed ID: 15921393
[TBL] [Abstract][Full Text] [Related]
12. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies.
García-Suárez J; de Miguel D; Krsnik I; Bañas H; Arribas I; Burgaleta C
Am J Hematol; 2005 Dec; 80(4):271-81. PubMed ID: 16315252
[TBL] [Abstract][Full Text] [Related]
13. Management of infections by the human polyomavirus JC: past, present and future.
Hou J; Major E
Expert Rev Anti Infect Ther; 2005 Aug; 3(4):629-40. PubMed ID: 16107201
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in autoimmune hematologic diseases: not just a matter of B cells.
Stasi R
Semin Hematol; 2010 Apr; 47(2):170-9. PubMed ID: 20350664
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
16. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
[TBL] [Abstract][Full Text] [Related]
17. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases.
Boren EJ; Cheema GS; Naguwa SM; Ansari AA; Gershwin ME
J Autoimmun; 2008; 30(1-2):90-8. PubMed ID: 18191544
[TBL] [Abstract][Full Text] [Related]
18. [Hepatitis B virus reactivation after cessation of prophylactic lamivudine therapy in B-cell lymphoma patients treated with rituximab combined CHOP therapy].
Mimura N; Tsujimura H; Ise M; Sakai C; Kojima H; Fukai K; Yokosuka O; Takagi T; Kumagai K
Rinsho Ketsueki; 2009 Dec; 50(12):1715-9. PubMed ID: 20068280
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy.
Koo YX; Tan DS; Tan IB; Tao M; Chow WC; Lim ST
Cancer; 2010 Jan; 116(1):115-21. PubMed ID: 19899164
[TBL] [Abstract][Full Text] [Related]
20. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?
Verbeeck J; Van Assche G; Ryding J; Wollants E; Rans K; Vermeire S; Pourkarim MR; Noman M; Dillner J; Van Ranst M; Rutgeerts P
Gut; 2008 Oct; 57(10):1393-7. PubMed ID: 18436577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]